Biosion

BIOSION ACHIEVEMENTS

Biosion is committed to developing therapies that will have significant impact in treating patients worldwide with immune and oncologic diseases.

Our best-in-class and first-in-class portfolio is designed to address significant unmet medical needs through the development of mono and bi-specific protein therapeutics, antibody drug conjugates and macrophage reprogramming agents

5

Assets in clinical development
3

Proprietary technology platforms
10+

Innovative therapies in preclinical or clinical development
12

Partnered programs

A Diversified Portfolio with Global Vision
Patient-centric focus is integral to Biosion’s R&D strategy
Portfolio of differentiated biologics to compete on the global stage

RICH PIPELINE OF
BREAKTHROUGH THERAPEUTICS

Download Overview

Molecule: BSI-045B

Modality / Target:

TSLP
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-502

Modality / Target:

bsAb, targets undisclosed
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-038

Modality / Target:

CD40
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-060T

Modality / Target:

Siglec-15
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-585

Modality / Target:

PD1/ILT4
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-04702

Modality / Target:

TROP2 ADC
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-082

Modality / Target:

SIRPα
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-001

Modality / Target:

HER2
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-510

Modality / Target:

bsAb, targets undisclosed
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-075

Modality / Target:

PVRIG
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-500

Modality / Target:

bsAb, targets undisclosed
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-715

Modality / Target:

ADC, targets undisclosed
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-712

Modality / Target:

ADC, targets undisclosed
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-709

Modality / Target:

ADC, targets undisclosed
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ImmunoGen

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Biosion’s Mission

To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide

Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA

BD@Biosion.com

1-302-998-5126